-
1
-
-
22044440425
-
Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma
-
DOI 10.1182/blood-2005-01-0034
-
Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106:296-303 (Pubitemid 40967205)
-
(2005)
Blood
, vol.106
, Issue.1
, pp. 296-303
-
-
Bergsagel, P.L.1
Kuehl, W.M.2
Zhan, F.3
Sawyer, J.4
Barlogie, B.5
Shaughnessy Jr., J.6
-
2
-
-
77954499305
-
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
-
Blum W, Phelps MA, Klisovic RB, Rozewski DM, Ni W, Albanese KA, Rovin B, Kefauver C, Devine SM, Lucas DM, Johnson A, Schaaf LJ, Byrd JC, Marcucci G, Grever MR (2010) Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica 95:1098-1105
-
(2010)
Haematologica
, vol.95
, pp. 1098-1105
-
-
Blum, W.1
Phelps, M.A.2
Klisovic, R.B.3
Rozewski, D.M.4
Ni, W.5
Albanese, K.A.6
Rovin, B.7
Kefauver, C.8
Devine, S.M.9
Lucas, D.M.10
Johnson, A.11
Schaaf, L.J.12
Byrd, J.C.13
Marcucci, G.14
Grever, M.R.15
-
3
-
-
33846219417
-
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
-
DOI 10.1182/blood-2006-05-020735
-
Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, Colevas AD, Grever MR (2007) Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109:399-404 (Pubitemid 46105932)
-
(2007)
Blood
, vol.109
, Issue.2
, pp. 399-404
-
-
Byrd, J.C.1
Lin, T.S.2
Dalton, J.T.3
Wu, D.4
Phelps, M.A.5
Fischer, B.6
Moran, M.7
Blum, K.A.8
Rovin, B.9
Brooker-McEldowney, M.10
Broering, S.11
Schaaf, L.J.12
Johnson, A.J.13
Lucas, D.M.14
Heerema, N.A.15
Lozanski, G.16
Young, D.C.17
Suarez, J.-R.18
Colevas, A.D.19
Grever, M.R.20
more..
-
4
-
-
0035943710
-
Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo
-
Chao SH, Price DH (2001) Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 276:31793-31799
-
(2001)
J Biol Chem
, vol.276
, pp. 31793-31799
-
-
Chao, S.H.1
Price, D.H.2
-
5
-
-
0035835827
-
p107 and p130: Versatile proteins with interesting pockets
-
DOI 10.1006/excr.2000.5135
-
Classon M, Dyson N (2001) p107 and p130: versatile proteins with interesting pockets. Exp Cell Res 264:135-147 (Pubitemid 32989088)
-
(2001)
Experimental Cell Research
, vol.264
, Issue.1
, pp. 135-147
-
-
Classon, M.1
Dyson, N.2
-
6
-
-
18344383345
-
Pocket proteins and cell cycle control
-
Cobrinik D (2005) Pocket proteins and cell cycle control. Oncogene 24:2796-2809
-
(2005)
Oncogene
, vol.24
, pp. 2796-2809
-
-
Cobrinik, D.1
-
7
-
-
33645231619
-
Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entry
-
Dai Y, Hamm TE, Dent P, Grant S (2006) Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entry. Cell Cycle 5:437-446
-
(2006)
Cell Cycle
, vol.5
, pp. 437-446
-
-
Dai, Y.1
Hamm, T.E.2
Dent, P.3
Grant, S.4
-
9
-
-
33645393211
-
Flavopiridol in patients with relapsed or refractory multiple myeloma: A phase 2 trial with clinical and pharmacodynamic end-points
-
Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Fitch TR, Fenton RG, Fonseca R, Isham CR, Ziesmer SC, Erlichman C, Bible KC (2006) Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. Haematologica 91:390-393
-
(2006)
Haematologica
, vol.91
, pp. 390-393
-
-
Dispenzieri, A.1
Gertz, M.A.2
Lacy, M.Q.3
Geyer, S.M.4
Fitch, T.R.5
Fenton, R.G.6
Fonseca, R.7
Isham, C.R.8
Ziesmer, S.C.9
Erlichman, C.10
Bible, K.C.11
-
10
-
-
84988241358
-
International uniform response criteria for multiple myeloma
-
DOI 10.1038/sj.leu.2404284, PII 2404284
-
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473 (Pubitemid 44264086)
-
(2006)
Leukemia
, vol.20
, Issue.9
, pp. 1467-1473
-
-
Durie, B.G.M.1
Harousseau, J.-L.2
Miguel, J.S.3
Blade, J.4
Barlogie, B.5
Anderson, K.6
Gertz, M.7
Dimopoulos, M.8
Westin, J.9
Sonneveld, P.10
Ludwig, H.11
Gahrton, G.12
Beksac, M.13
Crowley, J.14
Belch, A.15
Boccadaro, M.16
Turesson, I.17
Joshua, D.18
Vesole, D.19
Kyle, R.20
Alexanian, R.21
Tricot, G.22
Attal, M.23
Merlini, G.24
Powles, R.25
Richardson, P.26
Shimizu, K.27
Tosi, P.28
Morgan, G.29
Rajkumar, S.V.30
more..
-
11
-
-
84988241358
-
International uniform response criteria for multiple myeloma
-
DOI 10.1038/sj.leu.2404284, PII 2404284
-
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473 (Pubitemid 44264086)
-
(2006)
Leukemia
, vol.20
, Issue.9
, pp. 1467-1473
-
-
Durie, B.G.M.1
Harousseau, J.-L.2
Miguel, J.S.3
Blade, J.4
Barlogie, B.5
Anderson, K.6
Gertz, M.7
Dimopoulos, M.8
Westin, J.9
Sonneveld, P.10
Ludwig, H.11
Gahrton, G.12
Beksac, M.13
Crowley, J.14
Belch, A.15
Boccadaro, M.16
Turesson, I.17
Joshua, D.18
Vesole, D.19
Kyle, R.20
Alexanian, R.21
Tricot, G.22
Attal, M.23
Merlini, G.24
Powles, R.25
Richardson, P.26
Shimizu, K.27
Tosi, P.28
Morgan, G.29
Rajkumar, S.V.30
more..
-
12
-
-
0036850211
-
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1
-
Gojo I, Zhang B, Fenton RG (2002) The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 8:3527-3538 (Pubitemid 35340731)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.11
, pp. 3527-3538
-
-
Gojo, I.1
Zhang, B.2
Fenton, R.G.3
-
13
-
-
79956036001
-
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms
-
Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD Sr, Kolla S, Doyle A, Wright J, Sullivan DM, Roberts JD, Grant S (2011) Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res 17:3388-3397
-
(2011)
Clin Cancer Res
, vol.17
, pp. 3388-3397
-
-
Holkova, B.1
Perkins, E.B.2
Ramakrishnan, V.3
Tombes, M.B.4
Shrader, E.5
Talreja, N.6
Wellons, M.D.7
Hogan, K.T.8
Roodman, G.D.9
Coppola, D.10
Kang, L.11
Dawson, J.12
Stuart, R.K.13
Peer, C.14
Figg Sr., W.D.15
Kolla, S.16
Doyle, A.17
Wright, J.18
Sullivan, D.M.19
Roberts, J.D.20
Grant, S.21
more..
-
14
-
-
42449097201
-
Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium
-
Hussain SR, Lucas DM, Johnson AJ, Lin TS, Bakaletz AP, Dang VX, Viatchenko-Karpinski S, Ruppert AS, Byrd JC, Kuppusamy P, Crouser ED, Grever MR (2008) Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood 111:3190-3199
-
(2008)
Blood
, vol.111
, pp. 3190-3199
-
-
Hussain, S.R.1
Lucas, D.M.2
Johnson, A.J.3
Lin, T.S.4
Bakaletz, A.P.5
Dang, V.X.6
Viatchenko-Karpinski, S.7
Ruppert, A.S.8
Byrd, J.C.9
Kuppusamy, P.10
Crouser, E.D.11
Grever, M.R.12
-
15
-
-
0036736587
-
Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma
-
Kramer A, Schultheis B, Bergmann J, Willer A, Hegenbart U, Ho AD, Goldschmidt H, Hehlmann R (2002) Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma. Leukemia 16:1844-1851
-
(2002)
Leukemia
, vol.16
, pp. 1844-1851
-
-
Kramer, A.1
Schultheis, B.2
Bergmann, J.3
Willer, A.4
Hegenbart, U.5
Ho, A.D.6
Goldschmidt, H.7
Hehlmann, R.8
-
16
-
-
41949130070
-
Improved survival in multiple myeloma and the impact of novel therapies
-
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520
-
(2008)
Blood
, vol.111
, pp. 2516-2520
-
-
Kumar, S.K.1
Rajkumar, S.V.2
Dispenzieri, A.3
Lacy, M.Q.4
Hayman, S.R.5
Buadi, F.K.6
Zeldenrust, S.R.7
Dingli, D.8
Russell, S.J.9
Lust, J.A.10
Greipp, P.R.11
Kyle, R.A.12
Gertz, M.A.13
-
17
-
-
79960220394
-
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response
-
Lopez-Girona A, Heintel D, Zhang LH, Mendy D, Gaidarova S, Brady H, Bartlett JB, Schafer PH, Schreder M, Bolomsky A, Hilgarth B, Zojer N, Gisslinger H, Ludwig H, Daniel T, Jager U, Chopra R (2011) Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 154:325-336
-
(2011)
Br J Haematol
, vol.154
, pp. 325-336
-
-
Lopez-Girona, A.1
Heintel, D.2
Zhang, L.H.3
Mendy, D.4
Gaidarova, S.5
Brady, H.6
Bartlett, J.B.7
Schafer, P.H.8
Schreder, M.9
Bolomsky, A.10
Hilgarth, B.11
Zojer, N.12
Gisslinger, H.13
Ludwig, H.14
Daniel, T.15
Jager, U.16
Chopra, R.17
-
18
-
-
84865183563
-
ER stress and autophagy: New players in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
-
Mahoney E, Lucas DM, Gupta SV, Wagner AJ, Herman SEM, Smith LL, Yeh Y-Y, Andritsos L, Jones JA, Flynn JM, Blum KA, Zhang X, Lehman A, Kong H, Gurcan M, Grever MR, Johnson AJ, Byrd JC (2012) ER stress and autophagy: new players in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood 120:1262-1273
-
(2012)
Blood
, vol.120
, pp. 1262-1273
-
-
Mahoney, E.1
Lucas, D.M.2
Gupta, S.V.3
Wagner, A.J.4
Herman, S.E.M.5
Smith, L.L.6
Yeh, Y.-Y.7
Andritsos, L.8
Jones, J.A.9
Flynn, J.M.10
Blum, K.A.11
Zhang, X.12
Lehman, A.13
Kong, H.14
Gurcan, M.15
Grever, M.R.16
Johnson, A.J.17
Byrd, J.C.18
-
19
-
-
9244239811
-
G1 cell-cycle control and cancer
-
Massague J (2004) G1 cell-cycle control and cancer. Nature 432:298-306
-
(2004)
Nature
, vol.432
, pp. 298-306
-
-
Massague, J.1
-
20
-
-
78851470347
-
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: Biological and clinical implications
-
McMillin DW, Delmore J, Negri J, Buon L, Jacobs HM, Laubach J, Jakubikova J, Ooi M, Hayden P, Schlossman R, Munshi NC, Lengauer C, Richardson PG, Anderson KC, Mitsiades CS (2011) Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol 152:420-432
-
(2011)
Br J Haematol
, vol.152
, pp. 420-432
-
-
McMillin, D.W.1
Delmore, J.2
Negri, J.3
Buon, L.4
Jacobs, H.M.5
Laubach, J.6
Jakubikova, J.7
Ooi, M.8
Hayden, P.9
Schlossman, R.10
Munshi, N.C.11
Lengauer, C.12
Richardson, P.G.13
Anderson, K.C.14
Mitsiades, C.S.15
-
21
-
-
63849246351
-
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
-
Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Brooker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, Dalton JT (2009) Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 113:2637-2645
-
(2009)
Blood
, vol.113
, pp. 2637-2645
-
-
Phelps, M.A.1
Lin, T.S.2
Johnson, A.J.3
Hurh, E.4
Rozewski, D.M.5
Farley, K.L.6
Wu, D.7
Blum, K.A.8
Fischer, B.9
Mitchell, S.M.10
Moran, M.E.11
Brooker-McEldowney, M.12
Heerema, N.A.13
Jarjoura, D.14
Schaaf, L.J.15
Byrd, J.C.16
Grever, M.R.17
Dalton, J.T.18
-
22
-
-
44449083839
-
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule
-
Phelps MA, Rozewski DM, Johnston JS, Farley KL, Albanese KA, Byrd JC, Lin TS, Grever MR, Dalton JT (2008) Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. J Chromatogr B Analyt Technol Biomed Life Sci 868:110-115
-
(2008)
J Chromatogr B Analyt Technol Biomed Life Sci
, vol.868
, pp. 110-115
-
-
Phelps, M.A.1
Rozewski, D.M.2
Johnston, J.S.3
Farley, K.L.4
Albanese, K.A.5
Byrd, J.C.6
Lin, T.S.7
Grever, M.R.8
Dalton, J.T.9
-
23
-
-
77951579858
-
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition
-
Santo L, Vallet S, Hideshima T, Cirstea D, Ikeda H, Pozzi S, Patel K, Okawa Y, Gorgun G, Perrone G, Calabrese E, Yule M, Squires M, Ladetto M, Boccadoro M, Richardson PG, Munshi NC, Anderson KC, Raje N (2010) AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene 29:2325-2336
-
(2010)
Oncogene
, vol.29
, pp. 2325-2336
-
-
Santo, L.1
Vallet, S.2
Hideshima, T.3
Cirstea, D.4
Ikeda, H.5
Pozzi, S.6
Patel, K.7
Okawa, Y.8
Gorgun, G.9
Perrone, G.10
Calabrese, E.11
Yule, M.12
Squires, M.13
Ladetto, M.14
Boccadoro, M.15
Richardson, P.G.16
Munshi, N.C.17
Anderson, K.C.18
Raje, N.19
-
24
-
-
0036138680
-
Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol
-
DOI 10.1016/S0145-2126(01)00103-5, PII S0145212601001035
-
Semenov I, Akyuz C, Roginskaya V, Chauhan D, Corey SJ (2002) Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leuk Res 26:271-280 (Pubitemid 34037024)
-
(2002)
Leukemia Research
, vol.26
, Issue.3
, pp. 271-280
-
-
Semenov, I.1
Akyuz, C.2
Roginskaya, V.3
Chauhan, D.4
Corey, S.J.5
-
25
-
-
47049120726
-
IRF4 addiction in multiple myeloma
-
DOI 10.1038/nature07064, PII NATURE07064
-
Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu X, Zhao H, Zeng Y, Chen B, Epstein J, Staudt LM (2008) IRF4 addiction in multiple myeloma. Nature 454:226-231 (Pubitemid 351969894)
-
(2008)
Nature
, vol.454
, Issue.7201
, pp. 226-231
-
-
Shaffer, A.L.1
Emre, N.C.T.2
Lamy, L.3
Ngo, V.N.4
Wright, G.5
Xiao, W.6
Powell, J.7
Dave, S.8
Yu, X.9
Zhao, H.10
Zeng, Y.11
Chen, B.12
Epstein, J.13
Staudt, L.M.14
-
26
-
-
0029849620
-
Cancer cell cycles
-
Sherr CJ (1996) Cancer cell cycles. Science 274:1672-1677
-
(1996)
Science
, vol.274
, pp. 1672-1677
-
-
Sherr, C.J.1
-
27
-
-
0034602691
-
Diverse karyotypic abnormalities of the c-myc locus associated with c- myc dysregulation and tumor progression in multiple myeloma
-
DOI 10.1073/pnas.97.1.228
-
Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A, Dewald G, Kirsch IR, Bergsagel PL, Kuehl WM (2000) Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA 97:228-233 (Pubitemid 30055813)
-
(2000)
Proceedings of the National Academy of Sciences of the United States of America
, vol.97
, Issue.1
, pp. 228-233
-
-
Shou, Y.1
Martelli, M.L.2
Gabrea, A.3
Qi, Y.4
Brents, L.A.5
Roschke, A.6
Dewald, G.7
Kirsch, I.R.8
Bergsagel, P.L.9
Kuehl, W.M.10
-
28
-
-
1042278138
-
Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation. Abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9
-
DOI 10.1074/jbc.M304546200
-
Takada Y, Aggarwal BB (2004) Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 279:4750-4759 (Pubitemid 38199070)
-
(2004)
Journal of Biological Chemistry
, vol.279
, Issue.6
, pp. 4750-4759
-
-
Takada, Y.1
Aggarwal, B.B.2
-
29
-
-
4143122204
-
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer
-
DOI 10.1158/1078-0432.CCR-04-0025
-
Tan AR, Yang X, Berman A, Zhai S, Sparreboom A, Parr AL, Chow C, Brahim JS, Steinberg SM, Figg WD, Swain SM (2004) Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res 10:5038-5047 (Pubitemid 39099778)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.15
, pp. 5038-5047
-
-
Tan, A.R.1
Yang, X.2
Berman, A.3
Zhai, S.4
Sparreboom, A.5
Parr, A.L.6
Chow, C.7
Brahim, J.S.8
Steinberg, S.M.9
Figg, W.D.10
Swain, S.M.11
-
30
-
-
80855156719
-
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
-
Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ, Stewart AK (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118:4771-4779
-
(2011)
Blood
, vol.118
, pp. 4771-4779
-
-
Zhu, Y.X.1
Braggio, E.2
Shi, C.X.3
Bruins, L.A.4
Schmidt, J.E.5
Van Wier, S.6
Chang, X.B.7
Bjorklund, C.C.8
Fonseca, R.9
Bergsagel, P.L.10
Orlowski, R.Z.11
Stewart, A.K.12
|